

【SR-10 メタアナリシス】

CQ		周術期トリプルネガティブ乳癌に対して、プラチナ製剤は推奨されるか？																																																			
P	早期トリプルネガティブ乳癌	I	プラチナ系化学療法薬を含むレジメン																																																		
C	その他化学療法薬レジメン	O	OS																																																		
研究デザイン		RCT	文献数	4																																																	
コード		Loibl S (GeparSixto), 2018 Iwase M, 2020 Li Q, 2020 Yu KD, 2020																																																			
モデル		Random effects	方法	Inverse variance																																																	
効果指標		GR	統合値	(-) P=																																																	
フォレスト プロット		<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Weight</th> <th>Hazard Ratio IV, Random, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>GeparSixto</td> <td>-0.511</td> <td>0.32</td> <td>35.6%</td> <td>0.60 [0.32, 1.12]</td> <td>2014</td> </tr> <tr> <td>Iwase M</td> <td>-2.12</td> <td>1.164</td> <td>7.8%</td> <td>0.12 [0.01, 1.18]</td> <td>2020</td> </tr> <tr> <td>Li Q</td> <td>-1.966</td> <td>0.669</td> <td>17.9%</td> <td>0.14 [0.04, 0.52]</td> <td>2020</td> </tr> <tr> <td>Yu KD</td> <td>-0.342</td> <td>0.272</td> <td>38.7%</td> <td>0.71 [0.42, 1.21]</td> <td>2020</td> </tr> <tr> <td colspan="3">Total (95% CI)</td> <td>100.0%</td> <td>0.44 [0.22, 0.87]</td> <td></td> </tr> <tr> <td colspan="6">Heterogeneity: Tau² = 0.25; Chi² = 6.85, df = 3 (P = 0.08); I² = 56%</td> </tr> <tr> <td colspan="6">Test for overall effect: Z = 2.35 (P = 0.02)</td> </tr> </tbody> </table>				Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% CI	Year	GeparSixto	-0.511	0.32	35.6%	0.60 [0.32, 1.12]	2014	Iwase M	-2.12	1.164	7.8%	0.12 [0.01, 1.18]	2020	Li Q	-1.966	0.669	17.9%	0.14 [0.04, 0.52]	2020	Yu KD	-0.342	0.272	38.7%	0.71 [0.42, 1.21]	2020	Total (95% CI)			100.0%	0.44 [0.22, 0.87]		Heterogeneity: Tau ² = 0.25; Chi ² = 6.85, df = 3 (P = 0.08); I ² = 56%						Test for overall effect: Z = 2.35 (P = 0.02)					
Study or Subgroup	log[Hazard Ratio]	SE	Weight	Hazard Ratio IV, Random, 95% CI	Year																																																
GeparSixto	-0.511	0.32	35.6%	0.60 [0.32, 1.12]	2014																																																
Iwase M	-2.12	1.164	7.8%	0.12 [0.01, 1.18]	2020																																																
Li Q	-1.966	0.669	17.9%	0.14 [0.04, 0.52]	2020																																																
Yu KD	-0.342	0.272	38.7%	0.71 [0.42, 1.21]	2020																																																
Total (95% CI)			100.0%	0.44 [0.22, 0.87]																																																	
Heterogeneity: Tau ² = 0.25; Chi ² = 6.85, df = 3 (P = 0.08); I ² = 56%																																																					
Test for overall effect: Z = 2.35 (P = 0.02)																																																					
		コメント：																																																			
ファンネル プロット																																																					
		コメント：																																																			
その他の解析					コメント：																																																
メタリグ レッション																																																					
感度分析																																																					

【SR-10 メタアナリシス】

CQ		周術期トリプルネガティブ乳癌に対して、プラチナ製剤は推奨されるか？																																																																			
P	早期トリプルネガティブ乳癌	I	プラチナ系化学療法薬を含むレジメン																																																																		
C	その他化学療法薬レジメン	O	EFS(DFS)																																																																		
研究デザイン	RCT	文献数	5																																																																		
コード	Loibl S (GeparSixto), 2018 Iwase M, 2020 Li Q, 2020 Yu KD, 2020 Du F, 2020																																																																				
モデル	Random effects	方法	Inverse variance																																																																		
効果指標	HR	統合値	(-) P=																																																																		
フォレスト プロット	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>log[Hazard Ratio]</th> <th>SE</th> <th>Platinum Total</th> <th>Non-platinum Total</th> <th>Weight</th> <th>Hazard Ratio IV, Random, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>GeparSixto</td> <td>-0.58</td> <td>0.257</td> <td>0</td> <td>0</td> <td>24.3%</td> <td>0.56 [0.34, 0.93]</td> <td>2014</td> </tr> <tr> <td>Zhang P</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td>Not estimable</td> <td>2016</td> </tr> <tr> <td>Du F</td> <td>0.104</td> <td>0.272</td> <td>0</td> <td>0</td> <td>23.4%</td> <td>1.11 [0.65, 1.89]</td> <td>2020</td> </tr> <tr> <td>Iwase M</td> <td>-1.514</td> <td>0.667</td> <td>0</td> <td>0</td> <td>8.4%</td> <td>0.22 [0.06, 0.81]</td> <td>2020</td> </tr> <tr> <td>Li Q</td> <td>-1.171</td> <td>0.418</td> <td>0</td> <td>0</td> <td>15.8%</td> <td>0.31 [0.14, 0.70]</td> <td>2020</td> </tr> <tr> <td>Yu KD</td> <td>-0.431</td> <td>0.199</td> <td>0</td> <td>0</td> <td>28.1%</td> <td>0.65 [0.44, 0.96]</td> <td>2020</td> </tr> <tr> <td>Total (95% CI)</td> <td></td> <td></td> <td>0</td> <td>0</td> <td>100.0%</td> <td>0.58 [0.37, 0.89]</td> <td></td> </tr> </tbody> </table> <p>Heterogeneity: Tau² = 0.13; Chi² = 9.93, df = 4 (P = 0.04); I² = 60% Test for overall effect: Z = 2.49 (P = 0.01)</p>					Study or Subgroup	log[Hazard Ratio]	SE	Platinum Total	Non-platinum Total	Weight	Hazard Ratio IV, Random, 95% CI	Year	GeparSixto	-0.58	0.257	0	0	24.3%	0.56 [0.34, 0.93]	2014	Zhang P	0	0	0	0		Not estimable	2016	Du F	0.104	0.272	0	0	23.4%	1.11 [0.65, 1.89]	2020	Iwase M	-1.514	0.667	0	0	8.4%	0.22 [0.06, 0.81]	2020	Li Q	-1.171	0.418	0	0	15.8%	0.31 [0.14, 0.70]	2020	Yu KD	-0.431	0.199	0	0	28.1%	0.65 [0.44, 0.96]	2020	Total (95% CI)			0	0	100.0%	0.58 [0.37, 0.89]	
Study or Subgroup	log[Hazard Ratio]	SE	Platinum Total	Non-platinum Total	Weight	Hazard Ratio IV, Random, 95% CI	Year																																																														
GeparSixto	-0.58	0.257	0	0	24.3%	0.56 [0.34, 0.93]	2014																																																														
Zhang P	0	0	0	0		Not estimable	2016																																																														
Du F	0.104	0.272	0	0	23.4%	1.11 [0.65, 1.89]	2020																																																														
Iwase M	-1.514	0.667	0	0	8.4%	0.22 [0.06, 0.81]	2020																																																														
Li Q	-1.171	0.418	0	0	15.8%	0.31 [0.14, 0.70]	2020																																																														
Yu KD	-0.431	0.199	0	0	28.1%	0.65 [0.44, 0.96]	2020																																																														
Total (95% CI)			0	0	100.0%	0.58 [0.37, 0.89]																																																															
	コメント：																																																																				
ファンネル プロット																																																																					
	コメント：																																																																				
その他の解析					コメント：																																																																
メタリグ レッション																																																																					
感度分析																																																																					

【SR-10 メタアナリシス】

CQ		周術期トリプルネガティブ乳癌に対して、プラチナ製剤は推奨されるか？																																																																																																																														
P	早期トリプルネガティブ乳癌	I	プラチナ系化学療法薬を含むレジメン																																																																																																																													
C	その他化学療法薬レジメン	O	pCR																																																																																																																													
研究デザイン	RCT	文献数	9																																																																																																																													
コード	Alba E (GEICAM/2006-03), 2012 Ando M, 2014 von Minckwitz G (GeparSixto), 2014 Sikov WM (CALGB 40603), 2015 Zhang P, 2016 Loibl S (BrighTNess), 2018 Gluz O (WSG-ADAPT-TN), 2018 Schneeweiss A (GeparOcto), 2019 Tung N (INFORM), 2020																																																																																																																															
モデル	Random effects	方法	Mantel-Haenszel																																																																																																																													
効果指標	OR	統合値	(-) P=																																																																																																																													
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Platinum</th> <th colspan="2">Non-platinum</th> <th rowspan="2">Weight</th> <th colspan="2">Odds Ratio</th> <th rowspan="2">Year</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>M-H, Random, 95% CI</th> </tr> </thead> <tbody> <tr> <td>GEICAM/2006-03</td> <td>14</td> <td>47</td> <td>16</td> <td>46</td> <td>8.1%</td> <td>0.80</td> <td>[0.33, 1.90]</td> <td>2012</td> </tr> <tr> <td>Ando M</td> <td>23</td> <td>37</td> <td>10</td> <td>38</td> <td>7.0%</td> <td>4.60</td> <td>[1.72, 12.27]</td> <td>2014</td> </tr> <tr> <td>GeparSixto</td> <td>84</td> <td>158</td> <td>58</td> <td>157</td> <td>14.0%</td> <td>1.94</td> <td>[1.24, 3.04]</td> <td>2014</td> </tr> <tr> <td>CALGB 40603</td> <td>120</td> <td>221</td> <td>87</td> <td>212</td> <td>15.2%</td> <td>1.71</td> <td>[1.17, 2.50]</td> <td>2015</td> </tr> <tr> <td>I-SPYZ</td> <td>20</td> <td>39</td> <td>5</td> <td>21</td> <td></td> <td>Not estimable</td> <td></td> <td>2016</td> </tr> <tr> <td>Zhang P</td> <td>17</td> <td>44</td> <td>6</td> <td>43</td> <td>6.3%</td> <td>3.88</td> <td>[1.35, 11.15]</td> <td>2016</td> </tr> <tr> <td>BrighTNess</td> <td>92</td> <td>160</td> <td>49</td> <td>158</td> <td>13.8%</td> <td>3.01</td> <td>[1.90, 4.77]</td> <td>2018</td> </tr> <tr> <td>WSG-ADAPT-TN</td> <td>67</td> <td>146</td> <td>51</td> <td>178</td> <td>13.8%</td> <td>2.11</td> <td>[1.33, 3.35]</td> <td>2018</td> </tr> <tr> <td>GeparOcto</td> <td>105</td> <td>203</td> <td>97</td> <td>200</td> <td>15.0%</td> <td>1.14</td> <td>[0.77, 1.68]</td> <td>2019</td> </tr> <tr> <td>INFORM</td> <td>10</td> <td>44</td> <td>11</td> <td>38</td> <td>6.9%</td> <td>0.72</td> <td>[0.27, 1.95]</td> <td>2020</td> </tr> <tr> <td>Total (95% CI)</td> <td colspan="2">1060</td> <td colspan="2">1070</td> <td>100.0%</td> <td>1.82</td> <td>[1.32, 2.52]</td> <td></td> </tr> <tr> <td>Total events</td> <td colspan="2">532</td> <td colspan="2">385</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p> Heterogeneity: $\tau^2 = 0.14$; $\chi^2 = 22.90$, $df = 8$ ($P = 0.003$); $I^2 = 65\%$ Test for overall effect: $Z = 3.62$ ($P = 0.0003$) </p>					Study or Subgroup	Platinum		Non-platinum		Weight	Odds Ratio		Year	Events	Total	Events	Total	M-H, Random, 95% CI	M-H, Random, 95% CI	GEICAM/2006-03	14	47	16	46	8.1%	0.80	[0.33, 1.90]	2012	Ando M	23	37	10	38	7.0%	4.60	[1.72, 12.27]	2014	GeparSixto	84	158	58	157	14.0%	1.94	[1.24, 3.04]	2014	CALGB 40603	120	221	87	212	15.2%	1.71	[1.17, 2.50]	2015	I-SPYZ	20	39	5	21		Not estimable		2016	Zhang P	17	44	6	43	6.3%	3.88	[1.35, 11.15]	2016	BrighTNess	92	160	49	158	13.8%	3.01	[1.90, 4.77]	2018	WSG-ADAPT-TN	67	146	51	178	13.8%	2.11	[1.33, 3.35]	2018	GeparOcto	105	203	97	200	15.0%	1.14	[0.77, 1.68]	2019	INFORM	10	44	11	38	6.9%	0.72	[0.27, 1.95]	2020	Total (95% CI)	1060		1070		100.0%	1.82	[1.32, 2.52]		Total events	532		385					
Study or Subgroup	Platinum		Non-platinum		Weight		Odds Ratio		Year																																																																																																																							
	Events	Total	Events	Total		M-H, Random, 95% CI	M-H, Random, 95% CI																																																																																																																									
GEICAM/2006-03	14	47	16	46	8.1%	0.80	[0.33, 1.90]	2012																																																																																																																								
Ando M	23	37	10	38	7.0%	4.60	[1.72, 12.27]	2014																																																																																																																								
GeparSixto	84	158	58	157	14.0%	1.94	[1.24, 3.04]	2014																																																																																																																								
CALGB 40603	120	221	87	212	15.2%	1.71	[1.17, 2.50]	2015																																																																																																																								
I-SPYZ	20	39	5	21		Not estimable		2016																																																																																																																								
Zhang P	17	44	6	43	6.3%	3.88	[1.35, 11.15]	2016																																																																																																																								
BrighTNess	92	160	49	158	13.8%	3.01	[1.90, 4.77]	2018																																																																																																																								
WSG-ADAPT-TN	67	146	51	178	13.8%	2.11	[1.33, 3.35]	2018																																																																																																																								
GeparOcto	105	203	97	200	15.0%	1.14	[0.77, 1.68]	2019																																																																																																																								
INFORM	10	44	11	38	6.9%	0.72	[0.27, 1.95]	2020																																																																																																																								
Total (95% CI)	1060		1070		100.0%	1.82	[1.32, 2.52]																																																																																																																									
Total events	532		385																																																																																																																													
ファンネル プロット	<p>コメント：</p>																																																																																																																															
その他の解析					コメント：																																																																																																																											
メタリグ レッション																																																																																																																																
感度分析																																																																																																																																

【SR-10 メタアナリシス】

CQ		周術期トリプルネガティブ乳癌に対して、プラチナ製剤は推奨されるか？																																																																																																																																																																									
P	早期トリプルネガティブ乳癌	I	プラチナ系化学療法薬を含むレジメン																																																																																																																																																																								
C	その他化学療法薬レジメン	O	Toxicity (neutropenia)																																																																																																																																																																								
研究デザイン	RCT	文献数	9																																																																																																																																																																								
コード	Ando M, 2014 von Minckwitz G (GeparSixto), 2014 Loibl S (BrightNess), 2018 Gluz O (WSG-ADAPT-TN), 2018 Schneeweiss A (GeparOcto), 2019 Tung N (INFORM), 2020 Li Q, 2020 Yu KD, 2020 Du F, 2020																																																																																																																																																																										
モデル	Random effects	方法	Mantel-Haenszel																																																																																																																																																																								
効果指標	RR	統合値	(-) P=																																																																																																																																																																								
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Platinum</th> <th colspan="2">Non-platinum</th> <th rowspan="2">Weight</th> <th colspan="2">Risk Ratio</th> <th rowspan="2">Year</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> <th>M-H, Random, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>GEICAM/2006-03</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td colspan="2">Not estimable</td> <td>2012</td> </tr> <tr> <td>Ando M</td> <td>14</td> <td>88</td> <td>0</td> <td>91</td> <td>13.9%</td> <td colspan="2">29.98 [1.82, 494.99]</td> <td>2014</td> </tr> <tr> <td>GeparSixto</td> <td>45</td> <td>295</td> <td>1</td> <td>293</td> <td>16.4%</td> <td colspan="2">44.69 [6.20, 322.10]</td> <td>2014</td> </tr> <tr> <td>CALGB 40603</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td colspan="2">Not estimable</td> <td>2015</td> </tr> <tr> <td>i-SPY2</td> <td>20</td> <td>72</td> <td>0</td> <td>44</td> <td></td> <td colspan="2">Not estimable</td> <td>2016</td> </tr> <tr> <td>Zhang P</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td colspan="2">Not estimable</td> <td>2016</td> </tr> <tr> <td>BrightNess</td> <td>27</td> <td>158</td> <td>0</td> <td>157</td> <td>13.9%</td> <td colspan="2">54.65 [3.36, 888.24]</td> <td>2018</td> </tr> <tr> <td>WSG-ADAPT-TN</td> <td>0</td> <td>151</td> <td>0</td> <td>180</td> <td></td> <td colspan="2">Not estimable</td> <td>2018</td> </tr> <tr> <td>GeparOcto</td> <td>20</td> <td>475</td> <td>36</td> <td>470</td> <td>19.7%</td> <td colspan="2">0.55 [0.32, 0.94]</td> <td>2019</td> </tr> <tr> <td>Du F</td> <td>3</td> <td>154</td> <td>2</td> <td>154</td> <td>17.0%</td> <td colspan="2">1.50 [0.25, 8.85]</td> <td>2020</td> </tr> <tr> <td>INFORM</td> <td>0</td> <td>60</td> <td>0</td> <td>57</td> <td></td> <td colspan="2">Not estimable</td> <td>2020</td> </tr> <tr> <td>Li Q</td> <td>0</td> <td>70</td> <td>0</td> <td>73</td> <td></td> <td colspan="2">Not estimable</td> <td>2020</td> </tr> <tr> <td>Yu KD</td> <td>32</td> <td>322</td> <td>5</td> <td>320</td> <td>19.1%</td> <td colspan="2">6.36 [2.51, 16.12]</td> <td>2020</td> </tr> <tr> <td>Total (95% CI)</td> <td colspan="2">1773</td> <td colspan="2">1795</td> <td>100.0%</td> <td colspan="2">7.07 [1.08, 46.34]</td> <td></td> </tr> <tr> <td>Total events</td> <td colspan="2">141</td> <td colspan="2">44</td> <td></td> <td colspan="2"></td> <td></td> </tr> <tr> <td colspan="9">Heterogeneity: Tau² = 4.59; Chi² = 57.60, df = 5 (P < 0.00001); I² = 91%</td> </tr> <tr> <td colspan="9">Test for overall effect: Z = 2.04 (P = 0.04)</td> </tr> </tbody> </table>			Study or Subgroup	Platinum		Non-platinum		Weight	Risk Ratio		Year	Events	Total	Events	Total	M-H, Random, 95% CI	Year	GEICAM/2006-03	0	0	0	0		Not estimable		2012	Ando M	14	88	0	91	13.9%	29.98 [1.82, 494.99]		2014	GeparSixto	45	295	1	293	16.4%	44.69 [6.20, 322.10]		2014	CALGB 40603	0	0	0	0		Not estimable		2015	i-SPY2	20	72	0	44		Not estimable		2016	Zhang P	0	0	0	0		Not estimable		2016	BrightNess	27	158	0	157	13.9%	54.65 [3.36, 888.24]		2018	WSG-ADAPT-TN	0	151	0	180		Not estimable		2018	GeparOcto	20	475	36	470	19.7%	0.55 [0.32, 0.94]		2019	Du F	3	154	2	154	17.0%	1.50 [0.25, 8.85]		2020	INFORM	0	60	0	57		Not estimable		2020	Li Q	0	70	0	73		Not estimable		2020	Yu KD	32	322	5	320	19.1%	6.36 [2.51, 16.12]		2020	Total (95% CI)	1773		1795		100.0%	7.07 [1.08, 46.34]			Total events	141		44						Heterogeneity: Tau ² = 4.59; Chi ² = 57.60, df = 5 (P < 0.00001); I ² = 91%									Test for overall effect: Z = 2.04 (P = 0.04)								
Study or Subgroup	Platinum		Non-platinum		Weight	Risk Ratio		Year																																																																																																																																																																			
	Events	Total	Events	Total		M-H, Random, 95% CI	Year																																																																																																																																																																				
GEICAM/2006-03	0	0	0	0		Not estimable		2012																																																																																																																																																																			
Ando M	14	88	0	91	13.9%	29.98 [1.82, 494.99]		2014																																																																																																																																																																			
GeparSixto	45	295	1	293	16.4%	44.69 [6.20, 322.10]		2014																																																																																																																																																																			
CALGB 40603	0	0	0	0		Not estimable		2015																																																																																																																																																																			
i-SPY2	20	72	0	44		Not estimable		2016																																																																																																																																																																			
Zhang P	0	0	0	0		Not estimable		2016																																																																																																																																																																			
BrightNess	27	158	0	157	13.9%	54.65 [3.36, 888.24]		2018																																																																																																																																																																			
WSG-ADAPT-TN	0	151	0	180		Not estimable		2018																																																																																																																																																																			
GeparOcto	20	475	36	470	19.7%	0.55 [0.32, 0.94]		2019																																																																																																																																																																			
Du F	3	154	2	154	17.0%	1.50 [0.25, 8.85]		2020																																																																																																																																																																			
INFORM	0	60	0	57		Not estimable		2020																																																																																																																																																																			
Li Q	0	70	0	73		Not estimable		2020																																																																																																																																																																			
Yu KD	32	322	5	320	19.1%	6.36 [2.51, 16.12]		2020																																																																																																																																																																			
Total (95% CI)	1773		1795		100.0%	7.07 [1.08, 46.34]																																																																																																																																																																					
Total events	141		44																																																																																																																																																																								
Heterogeneity: Tau ² = 4.59; Chi ² = 57.60, df = 5 (P < 0.00001); I ² = 91%																																																																																																																																																																											
Test for overall effect: Z = 2.04 (P = 0.04)																																																																																																																																																																											
ファンネル プロット	<p>コメント：</p>																																																																																																																																																																										
その他の解析			コメント：																																																																																																																																																																								
メタリグ レッション																																																																																																																																																																											
感度分析																																																																																																																																																																											

【SR-10 メタアナリシス】

CQ		周術期トリプルネガティブ乳癌に対して、プラチナ製剤は推奨されるか？																																																																																																																																																							
P	早期トリプルネガティブ乳癌	I	プラチナ系化学療法薬を含むレジメン																																																																																																																																																						
C	その他化学療法薬レジメン	O	Toxicity (neutropenia)																																																																																																																																																						
研究デザイン	RCT	文献数	12																																																																																																																																																						
コード	Alba E (GEICAM/2006-03), 2012 Ando M, 2014 von Minckwitz G (GeparSixto), 2014 Sikov WM (CALGB 40603), 2015 Zhang P, 2016 Loibl S (BrighTNess), 2018 Gluz O (WSG-ADAPT-TN), 2018 Schneeweiss A (GeparOcto), 2019 Tung N (INFORM), 2020 Li Q, 2020 Yu KD, 2020 Du F, 2020																																																																																																																																																								
モデル	Random effects	方法	Mantel-Haenszel																																																																																																																																																						
効果指標	RR	統合値	(-) P=																																																																																																																																																						
フォレスト プロット	<table border="1"> <thead> <tr> <th rowspan="2">Study or Subgroup</th> <th colspan="2">Platinum</th> <th colspan="2">Non-platinum</th> <th rowspan="2">Weight</th> <th rowspan="2">Risk Ratio M-H, Random, 95% CI</th> <th rowspan="2">Year</th> </tr> <tr> <th>Events</th> <th>Total</th> <th>Events</th> <th>Total</th> </tr> </thead> <tbody> <tr> <td>GEICAM/2006-03</td> <td>8</td> <td>47</td> <td>10</td> <td>46</td> <td>7.1%</td> <td>0.78 [0.34, 1.81]</td> <td>2012</td> </tr> <tr> <td>GeparSixto</td> <td>192</td> <td>295</td> <td>79</td> <td>293</td> <td>9.4%</td> <td>2.41 [1.96, 2.97]</td> <td>2014</td> </tr> <tr> <td>Ando M</td> <td>51</td> <td>88</td> <td>9</td> <td>91</td> <td>7.9%</td> <td>5.86 [3.07, 11.17]</td> <td>2014</td> </tr> <tr> <td>CALGB 40603</td> <td>63</td> <td>113</td> <td>24</td> <td>108</td> <td>8.9%</td> <td>2.51 [1.70, 3.70]</td> <td>2015</td> </tr> <tr> <td>I-SPY2</td> <td>51</td> <td>72</td> <td>1</td> <td>44</td> <td></td> <td>Not estimable</td> <td>2016</td> </tr> <tr> <td>Zhang P</td> <td>34</td> <td>47</td> <td>28</td> <td>44</td> <td>9.3%</td> <td>1.14 [0.86, 1.51]</td> <td>2016</td> </tr> <tr> <td>WSG-ADAPT-TN</td> <td>24</td> <td>151</td> <td>29</td> <td>180</td> <td>8.6%</td> <td>0.99 [0.60, 1.62]</td> <td>2018</td> </tr> <tr> <td>BrighTNess</td> <td>84</td> <td>158</td> <td>4</td> <td>157</td> <td>6.5%</td> <td>20.87 [7.84, 55.51]</td> <td>2018</td> </tr> <tr> <td>GeparOcto</td> <td>112</td> <td>475</td> <td>392</td> <td>470</td> <td>9.5%</td> <td>0.28 [0.24, 0.33]</td> <td>2019</td> </tr> <tr> <td>Du F</td> <td>67</td> <td>154</td> <td>100</td> <td>154</td> <td>9.4%</td> <td>0.67 [0.54, 0.83]</td> <td>2020</td> </tr> <tr> <td>INFORM</td> <td>4</td> <td>60</td> <td>5</td> <td>57</td> <td>5.3%</td> <td>0.76 [0.21, 2.69]</td> <td>2020</td> </tr> <tr> <td>Li Q</td> <td>15</td> <td>70</td> <td>35</td> <td>73</td> <td>8.5%</td> <td>0.45 [0.27, 0.74]</td> <td>2020</td> </tr> <tr> <td>Yu KD</td> <td>283</td> <td>322</td> <td>297</td> <td>320</td> <td>9.6%</td> <td>0.95 [0.90, 1.00]</td> <td>2020</td> </tr> <tr> <td>Total (95% CI)</td> <td colspan="2">1980</td> <td colspan="2">1993</td> <td>100.0%</td> <td>1.28 [0.83, 1.98]</td> <td></td> </tr> <tr> <td>Total events</td> <td colspan="2">937</td> <td colspan="2">1012</td> <td></td> <td></td> <td></td> </tr> <tr> <td colspan="8">Heterogeneity: Tau² = 0.51; Chi² = 392.38, df = 11 (P < 0.00001); I² = 97%</td> </tr> <tr> <td colspan="8">Test for overall effect: Z = 1.13 (P = 0.26)</td> </tr> </tbody> </table>					Study or Subgroup	Platinum		Non-platinum		Weight	Risk Ratio M-H, Random, 95% CI	Year	Events	Total	Events	Total	GEICAM/2006-03	8	47	10	46	7.1%	0.78 [0.34, 1.81]	2012	GeparSixto	192	295	79	293	9.4%	2.41 [1.96, 2.97]	2014	Ando M	51	88	9	91	7.9%	5.86 [3.07, 11.17]	2014	CALGB 40603	63	113	24	108	8.9%	2.51 [1.70, 3.70]	2015	I-SPY2	51	72	1	44		Not estimable	2016	Zhang P	34	47	28	44	9.3%	1.14 [0.86, 1.51]	2016	WSG-ADAPT-TN	24	151	29	180	8.6%	0.99 [0.60, 1.62]	2018	BrighTNess	84	158	4	157	6.5%	20.87 [7.84, 55.51]	2018	GeparOcto	112	475	392	470	9.5%	0.28 [0.24, 0.33]	2019	Du F	67	154	100	154	9.4%	0.67 [0.54, 0.83]	2020	INFORM	4	60	5	57	5.3%	0.76 [0.21, 2.69]	2020	Li Q	15	70	35	73	8.5%	0.45 [0.27, 0.74]	2020	Yu KD	283	322	297	320	9.6%	0.95 [0.90, 1.00]	2020	Total (95% CI)	1980		1993		100.0%	1.28 [0.83, 1.98]		Total events	937		1012					Heterogeneity: Tau ² = 0.51; Chi ² = 392.38, df = 11 (P < 0.00001); I ² = 97%								Test for overall effect: Z = 1.13 (P = 0.26)							
Study or Subgroup	Platinum		Non-platinum		Weight		Risk Ratio M-H, Random, 95% CI	Year																																																																																																																																																	
	Events	Total	Events	Total																																																																																																																																																					
GEICAM/2006-03	8	47	10	46	7.1%	0.78 [0.34, 1.81]	2012																																																																																																																																																		
GeparSixto	192	295	79	293	9.4%	2.41 [1.96, 2.97]	2014																																																																																																																																																		
Ando M	51	88	9	91	7.9%	5.86 [3.07, 11.17]	2014																																																																																																																																																		
CALGB 40603	63	113	24	108	8.9%	2.51 [1.70, 3.70]	2015																																																																																																																																																		
I-SPY2	51	72	1	44		Not estimable	2016																																																																																																																																																		
Zhang P	34	47	28	44	9.3%	1.14 [0.86, 1.51]	2016																																																																																																																																																		
WSG-ADAPT-TN	24	151	29	180	8.6%	0.99 [0.60, 1.62]	2018																																																																																																																																																		
BrighTNess	84	158	4	157	6.5%	20.87 [7.84, 55.51]	2018																																																																																																																																																		
GeparOcto	112	475	392	470	9.5%	0.28 [0.24, 0.33]	2019																																																																																																																																																		
Du F	67	154	100	154	9.4%	0.67 [0.54, 0.83]	2020																																																																																																																																																		
INFORM	4	60	5	57	5.3%	0.76 [0.21, 2.69]	2020																																																																																																																																																		
Li Q	15	70	35	73	8.5%	0.45 [0.27, 0.74]	2020																																																																																																																																																		
Yu KD	283	322	297	320	9.6%	0.95 [0.90, 1.00]	2020																																																																																																																																																		
Total (95% CI)	1980		1993		100.0%	1.28 [0.83, 1.98]																																																																																																																																																			
Total events	937		1012																																																																																																																																																						
Heterogeneity: Tau ² = 0.51; Chi ² = 392.38, df = 11 (P < 0.00001); I ² = 97%																																																																																																																																																									
Test for overall effect: Z = 1.13 (P = 0.26)																																																																																																																																																									
ファンネル プロット	<p>コメント：</p>																																																																																																																																																								
その他の解析					コメント：																																																																																																																																																				
メタリグ レッション																																																																																																																																																									
感度分析																																																																																																																																																									

【SR-10 メタアナリシス】

CQ		周術期トリプルネガティブ乳癌に対して、プラチナ製剤は推奨されるか？																																																																																																																																	
P	早期トリプルネガティブ乳癌	I	プラチナ系化学療法薬を含むレジメン																																																																																																																																
C	その他化学療法薬レジメン	O	Toxicity (thrombocytopenia)																																																																																																																																
研究デザイン	RCT	文献数	10																																																																																																																																
コード	Ando M, 2014 von Minckwitz G (GeparSixto), 2014 Sikov WM (CALGB 40603), 2015 Zhang P, 2016 Loibl S (BrighTNess), 2018 Gluz O (WSG-ADAPT-TN), 2018 Schneeweiss A (GeparOcto), 2019 Li Q, 2020 Yu KD, 2020 Du F, 2020																																																																																																																																		
モデル	Random effects	方法	Mantel-Haenszel																																																																																																																																
効果指標	RR	統合値	(-) P=																																																																																																																																
フォレスト プロット	<table border="1"> <thead> <tr> <th>Study or Subgroup</th> <th>Platinum Events</th> <th>Platinum Total</th> <th>Non-platinum Events</th> <th>Non-platinum Total</th> <th>Weight</th> <th>M-H, Random, 95% CI</th> <th>Year</th> </tr> </thead> <tbody> <tr> <td>GEICAM/2006-03</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td>Not estimable</td> <td>2012</td> </tr> <tr> <td>Ando M</td> <td>1</td> <td>88</td> <td>0</td> <td>91</td> <td>6.8%</td> <td>3.10 [0.13, 75.12]</td> <td>2014</td> </tr> <tr> <td>GeparSixto</td> <td>42</td> <td>295</td> <td>1</td> <td>293</td> <td>10.2%</td> <td>41.72 [5.78, 301.10]</td> <td>2014</td> </tr> <tr> <td>CALGB 40603</td> <td>23</td> <td>113</td> <td>4</td> <td>108</td> <td>13.2%</td> <td>5.50 [1.96, 15.37]</td> <td>2015</td> </tr> <tr> <td>I-SPY2</td> <td>15</td> <td>72</td> <td>0</td> <td>44</td> <td></td> <td>Not estimable</td> <td>2016</td> </tr> <tr> <td>Zhang P</td> <td>4</td> <td>47</td> <td>0</td> <td>44</td> <td>7.5%</td> <td>6.44 [0.47, 152.32]</td> <td>2016</td> </tr> <tr> <td>BrighTNess</td> <td>10</td> <td>158</td> <td>0</td> <td>157</td> <td>7.7%</td> <td>20.87 [1.23, 353.08]</td> <td>2018</td> </tr> <tr> <td>WSG-ADAPT-TN</td> <td>0</td> <td>151</td> <td>2</td> <td>180</td> <td>7.2%</td> <td>0.24 [0.01, 4.92]</td> <td>2018</td> </tr> <tr> <td>GeparOcto</td> <td>20</td> <td>475</td> <td>44</td> <td>470</td> <td>14.3%</td> <td>0.45 [0.27, 0.75]</td> <td>2019</td> </tr> <tr> <td>Du F</td> <td>6</td> <td>154</td> <td>5</td> <td>154</td> <td>12.8%</td> <td>1.20 [0.37, 3.85]</td> <td>2020</td> </tr> <tr> <td>INFORM</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td>Not estimable</td> <td>2020</td> </tr> <tr> <td>Li Q</td> <td>2</td> <td>70</td> <td>0</td> <td>73</td> <td>7.2%</td> <td>5.21 [0.25, 106.66]</td> <td>2020</td> </tr> <tr> <td>Yu KD</td> <td>15</td> <td>322</td> <td>5</td> <td>320</td> <td>13.2%</td> <td>2.98 [1.10, 8.11]</td> <td>2020</td> </tr> <tr> <td>Total (95% CI)</td> <td></td> <td>1873</td> <td>61</td> <td>1890</td> <td>100.0%</td> <td>3.14 [1.01, 9.72]</td> <td></td> </tr> <tr> <td>Total events</td> <td>123</td> <td></td> <td>61</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table> <p> Heterogeneity: Tau² = 2.25; Chi² = 52.04, df = 9 (P < 0.00001); I² = 83% Test for overall effect: Z = 1.98 (P = 0.05) </p>			Study or Subgroup	Platinum Events	Platinum Total	Non-platinum Events	Non-platinum Total	Weight	M-H, Random, 95% CI	Year	GEICAM/2006-03	0	0	0	0		Not estimable	2012	Ando M	1	88	0	91	6.8%	3.10 [0.13, 75.12]	2014	GeparSixto	42	295	1	293	10.2%	41.72 [5.78, 301.10]	2014	CALGB 40603	23	113	4	108	13.2%	5.50 [1.96, 15.37]	2015	I-SPY2	15	72	0	44		Not estimable	2016	Zhang P	4	47	0	44	7.5%	6.44 [0.47, 152.32]	2016	BrighTNess	10	158	0	157	7.7%	20.87 [1.23, 353.08]	2018	WSG-ADAPT-TN	0	151	2	180	7.2%	0.24 [0.01, 4.92]	2018	GeparOcto	20	475	44	470	14.3%	0.45 [0.27, 0.75]	2019	Du F	6	154	5	154	12.8%	1.20 [0.37, 3.85]	2020	INFORM	0	0	0	0		Not estimable	2020	Li Q	2	70	0	73	7.2%	5.21 [0.25, 106.66]	2020	Yu KD	15	322	5	320	13.2%	2.98 [1.10, 8.11]	2020	Total (95% CI)		1873	61	1890	100.0%	3.14 [1.01, 9.72]		Total events	123		61				
Study or Subgroup	Platinum Events	Platinum Total	Non-platinum Events	Non-platinum Total	Weight	M-H, Random, 95% CI	Year																																																																																																																												
GEICAM/2006-03	0	0	0	0		Not estimable	2012																																																																																																																												
Ando M	1	88	0	91	6.8%	3.10 [0.13, 75.12]	2014																																																																																																																												
GeparSixto	42	295	1	293	10.2%	41.72 [5.78, 301.10]	2014																																																																																																																												
CALGB 40603	23	113	4	108	13.2%	5.50 [1.96, 15.37]	2015																																																																																																																												
I-SPY2	15	72	0	44		Not estimable	2016																																																																																																																												
Zhang P	4	47	0	44	7.5%	6.44 [0.47, 152.32]	2016																																																																																																																												
BrighTNess	10	158	0	157	7.7%	20.87 [1.23, 353.08]	2018																																																																																																																												
WSG-ADAPT-TN	0	151	2	180	7.2%	0.24 [0.01, 4.92]	2018																																																																																																																												
GeparOcto	20	475	44	470	14.3%	0.45 [0.27, 0.75]	2019																																																																																																																												
Du F	6	154	5	154	12.8%	1.20 [0.37, 3.85]	2020																																																																																																																												
INFORM	0	0	0	0		Not estimable	2020																																																																																																																												
Li Q	2	70	0	73	7.2%	5.21 [0.25, 106.66]	2020																																																																																																																												
Yu KD	15	322	5	320	13.2%	2.98 [1.10, 8.11]	2020																																																																																																																												
Total (95% CI)		1873	61	1890	100.0%	3.14 [1.01, 9.72]																																																																																																																													
Total events	123		61																																																																																																																																
ファンネル プロット	<p>コメント：</p>																																																																																																																																		
その他の解析			コメント：																																																																																																																																
メタリグ レッション																																																																																																																																			
感度分析																																																																																																																																			